Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Madan Gopal Kundu"'
Publikováno v:
Health Services and Outcomes Research Methodology.
Assessment of study success using conditional power (CP), the predictive power of success (PPoS) and probability of success (PoS) is becoming increasingly common for resource optimization and adaption of trials in clinical investigation. Determinatio
Autor:
D. Feng, David Maag, Banu Arun, Shannon Puhalla, S. Bhattacharya, Madan Gopal Kundu, N. Khandelwal, Christine K. Ratajczak, Hans Wildiers, Bruce A. Bach, Véronique Diéras, J.P. Ayoub, Hyo S. Han, Michael Friedlander, Bella Kaufman
Publikováno v:
Annals of Oncology. 33:299-309
BACKGROUND: In the BROCADE3 trial, addition of the poly(ADP-ribose) polymerase inhibitor, veliparib, to carboplatin/paclitaxel improved progression-free survival (PFS) (hazard ratio 0.71, 95% confidence interval 0.57-0.88; P = 0.002) in patients with
Autor:
Hyo S. Han, Shannon Puhalla, Christine K. Ratajczak, Véronique Diéras, Banu Arun, Jean Pierre Ayoub, Hans Wildiers, Madan Gopal Kundu, David Maag, Michael Friedlander, Bruce A. Bach, Katherine M. Bell-McGuinn, Bella Kaufman
Publikováno v:
European Journal of Cancer. 154:35-45
BACKGROUND: Addition of veliparib to carboplatin-paclitaxel, with continuation of veliparib monotherapy if carboplatin-paclitaxel was discontinued, improved progression-free survival (PFS) in patients with germline BRCA-associated locally advanced/me
Autor:
Hyo S. Han, Bridget Riley-Gillis, Teresa Helsten, Bella Kaufman, Yuan Yuan, Michael Friedlander, Meijing Wu, Cyril Ramathal, Véronique Diéras, Erin Murphy, Jean-Pierre M. Ayoub, Madan Gopal Kundu, Banu Arun, Christine K. Ratajczak, David Maag, Shannon Puhalla, Hans Wildiers, Vered Stearns
Publikováno v:
Clinical Cancer Research. 27:4983-4993
Purpose: Safety, efficacy, and exploratory biomarker analyses were evaluated in patients with advanced HER2-negative germline breast cancer susceptibility gene (gBRCA)-associated breast cancer enrolled in the BROCADE3 trial who received crossover vel
Assessment of study success using conditional power (CP), the predictive power of success (PPoS) and probability of success (PoS) is becoming increasingly common for resource optimization and adaption of trials in clinical investigation. Determinatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7af72a467299c32fc6b7445727565858
https://doi.org/10.21203/rs.3.rs-930504/v1
https://doi.org/10.21203/rs.3.rs-930504/v1
Autor:
Erika P. Hamilton, Shekeab Jauhari, Kathleen N. Moore, Brian I. Rini, Robert McLeod, Jie Lin, Nanae Izumi, Madan Gopal Kundu, Yusuke Myobatake, Abderrahmane Laadem, Yutaka Noguchi, Julius Kirui, David R. Spigel
Publikováno v:
Journal of Clinical Oncology. 40:3002-3002
3002 Background: Cadherin 6 (CDH6) is part of the cadherin family, which is involved with cell-cell adhesion, organ development, and epithelial-mesenchymal transition. CDH6 is found to be overexpressed in various cancers, particularly RCC and OVC. DS
Autor:
Suzanne George, Michael C. Heinrich, Neeta Somaiah, Brian Andrew Van Tine, Robert McLeod, Abderrahmane Laadem, Ben Cheng, Satoshi Nishioka, Madan Gopal Kundu, Xiaozhong Qian, Yvonne Y. Lau, Brittany Tran, Prasanna Kumar, Ololade Dosunmu, Julia Shi, Yoichi Naito
Publikováno v:
Journal of Clinical Oncology. 40:11512-11512
11512 Background: GPR20 is selectively and abundantly expressed in GISTs, the most common sarcoma of digestive tract. DS-6157a is an anti-GPR20 antibody-drug conjugate with a novel tetrapeptide-based linker and DNA topoisomerase I inhibitor exatecan
Autor:
Clemens Seidel, Matthias Preusser, Antje Wick, Dmitry Bentsion, Minhee Won, Walter J. Curran, Suvajit Samanta, Earle Bain, Giuseppe Lombardi, Andrés F. Cardona, Tony J. C. Wang, Stephanie L. Pugh, Golnaz Moazami, Peter Ansell, Craig Gedye, Marian S. Macsai, Filip de Vos, Peixin Zhang, Mark R. Gilbert, Sigmund Hsu, Kenneth Aldape, Hui K Gan, Vincent Blot, Andrew B. Lassman, Richard A. Peterson, Erik P. Sulman, Madan Gopal Kundu, Minesh P. Mehta, Christine Lebrun-Frenay, Michael A. Vogelbaum
Publikováno v:
Neuro Oncol
BACKGROUND Approximately 50% of nGBMs harbor EGFR-amp. Depatuxizumab mafodotin (depatux-m) is an antibody drug conjugate: a monoclonal antibody that binds activated EGFR (wild-type and EGFRvIII mutant) linked to a microtubule-inhibitor toxin. Pre-cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96fb51b9cf133d6802c7a8c09ee05fd2
https://europepmc.org/articles/PMC6847524/
https://europepmc.org/articles/PMC6847524/
Autor:
Bridget Riley-Gillis, Véronique Diéras, Shannon Puhalla, Meijing Wu, Erin Murphy, Yuan Yuan, Hyo S. Han, Vered Stearns, Madan Gopal Kundu, Michael Friedlander, David Maag, Jean-Pierre M. Ayoub, Hans Wildiers, Cyril Ramathal, Teresa Helsten, Banu Arun, Bella Kaufman, Christine K. Ratajczak
Publikováno v:
Journal of Clinical Oncology. 38:1097-1097
1097 Background: In BROCADE3 (NCT02163694), addition of the PARP inhibitor (PARPi) V to CP improved PFS in patients (pts) with g BRCA-associated advanced breast cancer (hazard ratio 0.71 [95% CI 0.57–0.88], p = 0.002). Reversion mutations may accou
Autor:
Matthew W. Dudley, Hyo S. Han, Bruce A. Bach, Hans Wildiers, Michael Friedlander, Madan Gopal Kundu, Bella Kaufman, Jean-Pierre M. Ayoub, Christine K. Ratajczak, Banu Arun, Véronique Diéras, David Maag, Shannon Puhalla
Publikováno v:
Journal of Clinical Oncology. 38:1091-1091
1091 Background: In BROCADE3 (NCT02163694), addition of PARP inhibitor V to CP resulted in improved progression-free survival (PFS) (HR 0.71 [95% CI 0.57−0.88], p=0.002) in patients (pts) with advanced HER2-negative breast cancer and g BRCA1/2 muta